DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia.

Author(s): Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM

Affiliation(s): Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Publication date & source: 2011-02, Int J Gynaecol Obstet., 112(2):126-30. Epub 2010 Nov 19.

Publication type: Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

OBJECTIVE: To compare the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) with that of a low-dose combined oral contraceptive (COC) in reducing fibroid-related menorrhagia. METHODS: In this single-center, open, randomized clinical trial, 58 women with menorrhagia who desired contraception were randomized to receive a LNG-IUS or COC. The outcomes included treatment failure, defined as the need for another treatment; menstrual blood loss (MBL) by the alkaline hematin method and a pictorial assessment chart (PBAC); hemoglobin levels; and "lost days." RESULTS: Treatment failed in 6 women (23.1%) in the LNG-IUS group and 11 (37.9%) in the COC group, for a hazard ratio of 0.46 (95% CI, 0.17-1.17, P=0.101). Using the alkaline hematin test, the reduction of MBL was significantly greater in the LNG-IUS group (90.9% +/- 12.8% vs 13.4% +/- 11.1%; P<0.001). Using PBAC scores, the reduction was also significantly greater in the LNG-IUS group (88.0% +/- 16.5% vs 53.5% +/- 5 1.2%; P=0.02). Moreover, hemoglobin levels increased from 9.7 +/- 1.9g/dL to 11.7 +/- 1.2g/dL (P<0.001) and lost days decreased from 8.2 +/- 3.3 days to 1.3 +/- 1.5 days (P=0.003) in the LNG-IUS group. CONCLUSION: Although the rate of treatment failure was similar in both groups, the LNG-IUS was more effective in reducing MBL than the COC in women with fibroid-related menorrhagia. Copyright A(c) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017